5 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 9 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Unknown 1 |
Follow Deferoxamine: new trials by email Literature Review of Deferoxamine trials Research Report on Deferoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synergistic Minimally Invasive Surgery and Deferoxamine in ICH Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD) - Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage | Phase 2 / Phase 3 | Not yet recruiting | University of Illinois at Chicago | 240 | 2026-03-01 | 2025-10-10 |
| The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL Colchicine 0.5 mg, Deferoxamine Mesylate, Control (Standard treatment) - Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage | Phase 3 | Recruiting | The George Institute | 2000 | 2025-02-27 | 2026-07-08 |
| Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia Tocilizumab Injection, Deferoxamine - COVID19, Intensive Care Unit | Phase 3 | Unknown | Abderrahmane Mami Hospital | 260 | 2020-09-04 | 2020-08-27 |
| Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With Deferoxamine Irochel, Deferoxamine - Iron Overload Due to Repeated Red Blood Cell Transfusions, Thalassemia Majors (Beta-Thalassemia Major) | Phase 3 | Completed | Hamdard University | 132 | 2019-02-11 | 2026-08-25 |
| Amlodipine for Myocardial Iron in Thalassemia Standard Chelation, Amlodipine - Thalassemia | Phase 2 / Phase 3 | Completed | Aga Khan University | 20 | 2014-02-01 | 2017-06-29 |
| Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2012-02-01 | 2012-02-06 |
| Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions ICL670, deferoxamine - Beta-Thalassemia | Phase 3 | Completed | Novartis Pharmaceuticals | 595 | 2003-05-01 | 2012-04-19 |
| Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Deferiprone (L1), Desferrioxamine - Hemochromatosis | Phase 3 | Completed | Lipomed | 95 | 2002-01-01 | 2012-11-19 |
Iron Overload (4) · beta-Thalassemia (4) · Thalassemia (3) · Cerebral Hemorrhage (2) · Anemia, Sickle Cell (1) · COVID-19 (1) · Hemochromatosis (1) · Hemosiderosis (1) · Stroke (1)
Abderrahmane Mami Hospital (1) · Aga Khan University (1) · Ain Shams University (1) · Beni-Suef University (1) · Hamdard University (1) · Lipomed (1) · Novartis Pharmaceuticals (1) · The George Institute (1) · University of Illinois at Chicago (1)
Egypt (3) · Pakistan (2) · United States (2) · Australia (1) · China (1) · Saudi Arabia (1) · Tunisia (1) · Turkey (Türkiye) (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Amal M El-Beshlawy, Prof. Dr. (1) · Babar Hasan (1) · Gursant S. Atwal, MD (1) · Javed Iqbal, MBBS (1) · Mohsen S. Elalfy, professour (1) · Yesim Aydinok, Prof. Dr. (1)
PMID 37975597, PMID 17951527, PMID 18055982, PMID 18351337, PMID 22180427, PMID 25492271, PMID 25600572